Evercore ISI Group Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to $379
Portfolio Pulse from richadhand@benzinga.com
Evercore ISI Group analyst Liisa Bayko maintains an Outperform rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and raises the price target from $375 to $379.
June 26, 2023 | 3:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Evercore ISI Group maintains an Outperform rating on Vertex Pharmaceuticals and raises the price target from $375 to $379.
The raised price target by Evercore ISI Group analyst Liisa Bayko indicates a positive outlook for Vertex Pharmaceuticals. This could lead to increased investor confidence and a potential short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100